Artificial Blood and Plasma: Global Markets to 2027
Report Scope:
The report provides a detailed overview of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status and the potential commercial market for artificial blood products. The report includes a discussion of artificial oxygen carrier products manufacturing, product features, technology and methodology used, available results of laboratory and clinical tests, product effectiveness, and factors that are affecting the market. Further, it explains the major drivers and regional dynamics of the global artificial blood market and current trends within the industry.
The report concludes with a special look at the potential artificial blood products that may enter the blood market postapproval from international authorities. Detailed profiles of the key players in the global artificial blood market and the current development stages of their products have been included. Excluded from consideration are product physical and chemical properties, detailed and unpublished clinical/lab results on the products, and detailed methodology/techniques used for product production.
Report Includes:
The report provides a detailed overview of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status and the potential commercial market for artificial blood products. The report includes a discussion of artificial oxygen carrier products manufacturing, product features, technology and methodology used, available results of laboratory and clinical tests, product effectiveness, and factors that are affecting the market. Further, it explains the major drivers and regional dynamics of the global artificial blood market and current trends within the industry.
The report concludes with a special look at the potential artificial blood products that may enter the blood market postapproval from international authorities. Detailed profiles of the key players in the global artificial blood market and the current development stages of their products have been included. Excluded from consideration are product physical and chemical properties, detailed and unpublished clinical/lab results on the products, and detailed methodology/techniques used for product production.
Report Includes:
- 144 tables
- An overview of global market for artificial blood plasma
- Analyses of global market trends, with projections of compound annual growth rates (CAGRs) through 2027
- Identification of growth-driving factors influencing the artificial blood plasma market, as well as opportunities, restraints, and technological developments
- Profiles of leading companies in the market, including Alliance Pharmaceutical Corp., Baxter Healthcare Corp., Northfield Laboratories Inc., Sanguine Biosciences, and Therapure Biopharma Inc.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Contribution of the Study and Intended Audience
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts' Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Introduction
CHAPTER 3 MARKET OVERVIEW
Introduction
Is There a Problem with Human Blood?
Emerging Needs for Artificial Blood
Artificial Blood Will Be Useful in Dealing With the Risks of Infection
Artificial Blood Will Help to Decrease the Load on Donor Blood Supply
Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
Artificial Blood Has the Potential to Lower Costs of the Blood System
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Challenges in Artificial Blood Development
CHAPTER 4 MARKET ESTIMATION
Market Dynamics: Factors and Impact Analysis
Time factor
Product Preference
Regulatory Approvals
Product Demand
Product Acceptance
Cost and Effectiveness
Intense Competition in the Market
Clinical Trials
Technologies
Product Pricing
Patient Group
Global Potential Market
Surgeries and Death Cases
Market Penetration
CHAPTER 5 MARKET BY SOURCE
Introduction
Artificial Blood Developed From Human Blood
Artificial Blood Developed From Animal Blood
Artificial Blood Developed Using Recombinant Technology
Surface Modified Hemoglobin
Cross-Linked Hemoglobin
Polymerized Hemoglobin
CHAPTER 6 MARKET BY TYPE
Introduction
Perfluorocarbon Emulsions
General Characteristics of Perfluorocarbons
Emulsion Selection
Historical Developments of Perfluorocarbon Emulsions
First Generation of PFCs
Second Generation of PFCs
Third Generation of PFCs
Hemoglobin Based Oxygen Carriers
General Characteristics of HBOCs
Historical Events: - Hemoglobin Solutions
CHAPTER 7 MARKET BREAKDOWN BY APPLICATION
Introduction
Surgeries
Emergency Resuscitation
For Short-term Use
Where More Effective Than Human Blood
Rejections Due to Religious Beliefs
Global Potential Artificial Blood Market, by Application
CHAPTER 8 MARKET BREAKDOWN BY REGION
Introduction
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Asia Pacific
China
India
Japan
Australia
Rest of The World
Brazil
South Africa
CHAPTER 9 REGULATION AND PATENT REVIEW
Introduction
FDA Regulation
FDA Good Manufacturing Practices and Reporting
Patent Review
CHAPTER 10 COMPETITIVE LANDSCAPE
Introduction
CHAPTER 11 PRODUCT ANALYSIS
Introduction
Product Safety
Product Effectiveness
Product Cost
Legal Implications
Hemolink
Product offered by Hemosol BioPharma Inc.
Clinical Trials
HemAssist
Product offered by Baxter Healthcare Corp.
Hemopure
Product offered by Biopure Corp./OPK Biotech
Clinical Trials
HemoSpan
Product offered by Sangart, Inc.
Clinical Trials
HemoTech
Product offered by HemoBioTech, Inc.
Clinical Trials
DDFPe
Product offered by NuvOx Pharma LLC
Oxycyte
Product offered by Tenax Therapeutics Inc.
Clinical Trials
Oxygent
Product offered by Alliance Pharmaceutical Corp.
Clinical Trials
VIDAPHOR
Product offered by FluorO2 Therapeutics, Inc.
Clinical Trials
PHER-O2
Product offered by Sanguine Biosciences
Clinical Trials
POLYHEME
Product Offered by Northfield Laboratories Inc.
Clinical Trials
SANGUINATE
Product Offered by Prolong Pharmaceuticals, LLC
Clinical Trials
CHAPTER 12 COMPANY PROFILES
ALLIANCE PHARMACEUTICAL CORP
Business Overview
Company and Product Developments
BAXTER HEALTHCARE CORP.
Business Overview
Company and Product Developments
BIOPURE CORP.
Business Overview
FLUORO2 THERAPEUTICS,INC.
Business Overview
Company and Product Developments
HEMOBIOTECH, INC.
Business Overview
Company and Product Developments
NORTHFIELD LABORATORIES INC.
Business Overview
Company and Product developments
NUVOX PHARMA LLC.
Business Overview
Company and Product Developments
PROLONG PHARMACEUTICALS, LLC
Business Overview
Company and Product Developments
SANGART, INC.
Business Overview
SANGUINE BIOSCIENCES
Business Overview
Company and Product Developments
TENAX THERAPEUTICS INC.
Business Overview
Company and Product Developments
THERAPURE BIOPHARMA INC.
Business Overview
Company and Product Developments
CHAPTER 13 APPENDIX
Study Goals and Objectives
Reasons for Doing This Study
Contribution of the Study and Intended Audience
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts' Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Introduction
CHAPTER 3 MARKET OVERVIEW
Introduction
Is There a Problem with Human Blood?
Emerging Needs for Artificial Blood
Artificial Blood Will Be Useful in Dealing With the Risks of Infection
Artificial Blood Will Help to Decrease the Load on Donor Blood Supply
Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
Artificial Blood Has the Potential to Lower Costs of the Blood System
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Challenges in Artificial Blood Development
CHAPTER 4 MARKET ESTIMATION
Market Dynamics: Factors and Impact Analysis
Time factor
Product Preference
Regulatory Approvals
Product Demand
Product Acceptance
Cost and Effectiveness
Intense Competition in the Market
Clinical Trials
Technologies
Product Pricing
Patient Group
Global Potential Market
Surgeries and Death Cases
Market Penetration
CHAPTER 5 MARKET BY SOURCE
Introduction
Artificial Blood Developed From Human Blood
Artificial Blood Developed From Animal Blood
Artificial Blood Developed Using Recombinant Technology
Surface Modified Hemoglobin
Cross-Linked Hemoglobin
Polymerized Hemoglobin
CHAPTER 6 MARKET BY TYPE
Introduction
Perfluorocarbon Emulsions
General Characteristics of Perfluorocarbons
Emulsion Selection
Historical Developments of Perfluorocarbon Emulsions
First Generation of PFCs
Second Generation of PFCs
Third Generation of PFCs
Hemoglobin Based Oxygen Carriers
General Characteristics of HBOCs
Historical Events: - Hemoglobin Solutions
CHAPTER 7 MARKET BREAKDOWN BY APPLICATION
Introduction
Surgeries
Emergency Resuscitation
For Short-term Use
Where More Effective Than Human Blood
Rejections Due to Religious Beliefs
Global Potential Artificial Blood Market, by Application
CHAPTER 8 MARKET BREAKDOWN BY REGION
Introduction
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Asia Pacific
China
India
Japan
Australia
Rest of The World
Brazil
South Africa
CHAPTER 9 REGULATION AND PATENT REVIEW
Introduction
FDA Regulation
FDA Good Manufacturing Practices and Reporting
Patent Review
CHAPTER 10 COMPETITIVE LANDSCAPE
Introduction
CHAPTER 11 PRODUCT ANALYSIS
Introduction
Product Safety
Product Effectiveness
Product Cost
Legal Implications
Hemolink
Product offered by Hemosol BioPharma Inc.
Clinical Trials
HemAssist
Product offered by Baxter Healthcare Corp.
Hemopure
Product offered by Biopure Corp./OPK Biotech
Clinical Trials
HemoSpan
Product offered by Sangart, Inc.
Clinical Trials
HemoTech
Product offered by HemoBioTech, Inc.
Clinical Trials
DDFPe
Product offered by NuvOx Pharma LLC
Oxycyte
Product offered by Tenax Therapeutics Inc.
Clinical Trials
Oxygent
Product offered by Alliance Pharmaceutical Corp.
Clinical Trials
VIDAPHOR
Product offered by FluorO2 Therapeutics, Inc.
Clinical Trials
PHER-O2
Product offered by Sanguine Biosciences
Clinical Trials
POLYHEME
Product Offered by Northfield Laboratories Inc.
Clinical Trials
SANGUINATE
Product Offered by Prolong Pharmaceuticals, LLC
Clinical Trials
CHAPTER 12 COMPANY PROFILES
ALLIANCE PHARMACEUTICAL CORP
Business Overview
Company and Product Developments
BAXTER HEALTHCARE CORP.
Business Overview
Company and Product Developments
BIOPURE CORP.
Business Overview
FLUORO2 THERAPEUTICS,INC.
Business Overview
Company and Product Developments
HEMOBIOTECH, INC.
Business Overview
Company and Product Developments
NORTHFIELD LABORATORIES INC.
Business Overview
Company and Product developments
NUVOX PHARMA LLC.
Business Overview
Company and Product Developments
PROLONG PHARMACEUTICALS, LLC
Business Overview
Company and Product Developments
SANGART, INC.
Business Overview
SANGUINE BIOSCIENCES
Business Overview
Company and Product Developments
TENAX THERAPEUTICS INC.
Business Overview
Company and Product Developments
THERAPURE BIOPHARMA INC.
Business Overview
Company and Product Developments
CHAPTER 13 APPENDIX
LIST OF TABLES
Summary Table: Global Potential Artificial Blood Market by case type, Through 2027
Table 1: Historical Events Related to Blood Transfusion
Table 2: Potential Benefits and Application Areas of Artificial Blood
Table 3: The Challenges Associated With the Development of Artificial Blood
Table 4: Average Number of Blood Units Required During Particular Medical Condition
Table 5: Market Penetration Cases Based on Set of Assumptions
Table 6: Global Potential Artificial Blood Market by Case Type, Through 2027
Table 7: Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
Table 8: Pros and Cons of Artificial Blood Developed from Human Blood
Table 9: Pros and Cons of Artificial Blood Developed from Animal Blood
Table 10: Pros & Cons of Artificial Blood Developed from Recombinant Blood
Table 11: Summary of Acellular Hb-Based Oxygen Carriers
Table 12: Hemoglobin Based Oxygen Carrier Products and Approval Status
Table 13: Potential Clinical Applications of Oxygen Carriers
Table 14: Composition of PFC Emulsion Based Artificial Blood Products
Table 15: First-Generation Perfluorocarbon Emulsions Used in Medicine and Biology
Table 16: Comparative Study of Second-Generation PFCs
Table 17: PFC Emulsion Products and Current Status
Table 18: Comparative Study Between RBCs and HBOCs
Table 19: HBOC Solutions Transfusion: Side Effects and Possible Causes
Table 20: HBOC Products Developed by Various Companies
Table 21: Global Potential Artificial Blood Market, by Application, Through 2027
Table 22: United States: Potential Artificial Blood Market, Through 2027
Table 23: Canada: Potential Artificial Blood Market, Through 2027
Table 24: Mexico: Potential Artificial Blood Market, Through 2027
Table 25: Germany: Potential Artificial Blood Market, Through 2027
Table 26: France: Potential Artificial Blood Market, Through 2027
Table 27: U.K.: Potential Artificial Blood Market, Through 2027
Table 28: Italy: Potential Artificial Blood Market, Through 2027
Table 29: Spain: Potential Artificial Blood Market, Through 2027
Table 30: Russia: Potential Artificial Blood Market, Through 2027
Table 31: China: Potential Artificial Blood Market, Through 2027
Table 32: India: Potential Artificial Blood Market, Through 2027
Table 33: Japan: Potential Artificial Blood Market, Through 2027
Table 34: Australia: Potential Artificial Blood Market, Through 2027
Table 35: Brazil: Potential Artificial Blood Market, Through 2027
Table 36: South Africa: Potential Artificial Blood Market, Through 2027
Table 37: Summary of Three Clinical Trial Phases Recognized by FDA
Table 38: Hemolink: Raw Material and Method Overview
Table 39: Hemolink: Advantages and Disadvantages
Table 40: Hemolink Clinical Trials Details
Table 41: Hemolink Clinical Trial: Tracking Information
Table 42: Hemolink Clinical Trial: Descriptive Information
Table 43: Hemolink Clinical Trial: Recruitment Information
Table 44: Hemolink Clinical Trial: Administrative Information
Table 45: HemAssist: Raw Material and Method Overview
Table 46: HemAssist: Product Characteristics
Table 47: HemAssist: Advantages and Disadvantages
Table 48: Hemopure: Raw Material and Method Overview
Table 49: Hemopure: Product Characteristics
Table 50: Hemopure: Advantages and Disadvantages
Table 51: Hemopure: List of Clinical Trials Registered
Table 52: Hemopure Clinical Trial: Patient Information
Table 53: Hemopure Clinical Trial: Details
Table 54: Summary of the Red-Blood-Cell-Controlled Phase 2 and Phase 3 Clinical Trial Performed by Biopure Corp.
Table 55: Red-Blood-Cell-Controlled Clinical Trial Performed on Surgical Patients, by Dosage and Effects
Table 56: Hemopure Clinical Trial: Tracking Information
Table 57: Decriptive Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
Table 58: Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
Table 59: Administrative Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
Table 60: A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects
Table 61: Descriptive Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
Table 62: Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
Table 63: Administrative Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
Table 64: Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia
Table 65: Tracking Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
Table 66: Descriptive Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
Table 67: Recruitment Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
Table 68: Administrative Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
Table 69: Hemospan: Raw Material and Method Overview
Table 70: Hemospan: Product Characteristics
Table 71: Hemospan: Advantages and Disadvantages
Table 72: Clinical Studies with Hemospan: Completed and Ongoing
Table 73: Hemospan Clinical Trial: Details
Table 74: Hemospan Clinical Trial: Tracking Information
Table 75: Hemospan Clinical Trial: Descriptive Information
Table 76: Hemospan Clinical Trial: Recruitment Information
Table 77: Hemospan Clinical Trial: Administrative Information
Table 78: Hemotech: Raw Material and Method Overview
Table 79: HemoTech: Advantages and Disadvantages
Table 80: HemoTech Clinical Trials: Details
Table 81: HemoTech Clinical Trial: Tracking Information
Table 82: HemoTech Clinical Trial: Descriptive Information
Table 83: HemoTech Clinical Trial: Recruitment Information
Table 84: HemoTech Clinical Trial: Administrative Information
Table 85: DDFPe: Company Product Range and Description
Table 86: DDFPe: Raw Material and Method Overview
Table 87: DDFPe: Advantages and Disadvantages
Table 88: DDFPeClinical Trials: Details
Table 89: DDFPe Clinical Trial: Tracking Information
Table 90: DDFPe Clinical Trial: Descriptive Information
Table 91: DDFPe Clinical Trial: Recruitment Information
Table 92: DDFPe Clinical Trial: Administrative Information
Table 93: Oxycyte: Raw Material and Method Overview
Table 94: Oxycyte: Advantages and Disadvantages
Table 95: Oxycyte Clinical Trials: Details
Table 96: Oxycyte Clinical Trial: Tracking Information
Table 97: Descriptive Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
Table 98: Recruitment Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
Table 99: Administrative Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
Table 100: Details of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 101: Tracking Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 102: Descriptive Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 103: Recruitment Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 104: Administrative Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 105: Oxygent: Raw Material and Method Overview
Table 106: Oxygent: Advantages and Disadvantages
Table 107: Oxygent: Clinical Trials
Table 108: Vidaphor: Raw Material and Method Overview
Table 109: Vidaphor: Advantages and Disadvantages
Table 110: Vidaphor: Clinical Trial
Table 111: PHER-O2: Raw Material and Method Overview
Table 112: PHER-O2: Advantages and Disadvantages
Table 113: PHER-O2: Clinical Trials
Table 114: PolyHeme: Raw Material and Method Overview
Table 115: PolyHeme: Product Characteristics
Table 116: PolyHeme: Advantages and Disadvantages
Table 117: Polyheme Clinical Trials: Patient Information
Table 118: PolyHeme Clinical Trial: Details
Table 119: PolyHeme Clinical Trial: Tracking Information
Table 120: PolyHeme Clinical Trial: Descriptive Information
Table 121: PolyHeme Clinical Trial: Recruitment Information
Table 122: PolyHeme Clinical Trial: Administrative Information
Table 123: SANGUINATE: Raw Material and Method Overview
Table 124: SANGUINATE: Advantages and Disadvantages
Table 125: SANGUINATE: Clinical Trials
Table 126: SANGUINATE Clinical Trial: Details
Table 127: SANGUINATE Clinical Trial: Tracking Information
Table 128: SANGUINATE Clinical Trial: Descriptive Information
Table 129: SANGUINATE Clinical Trial: Recruitment Information
Table 130: SANGUINATE Clinical Trial: Administrative Information
Table 131: Alliance Pharmaceutical Corp: Company and Product Snapshot
Table 132: Baxter International Inc.: Company and Product Snapshot
Table 133: Biopure Corp: Company and Product Snapshot
Table 134: FluorO2 Therapeutics Inc.: Company and Product Snapshot
Table 135: HemoBioTech, Inc.: Company and Product Snapshot
Table 136: HemoBioTech, Inc.: Company and Product Snapshot
Table 137: Northfield Laboratories Inc.: Company and Product Snapshot
Table 138: Prolong Pharmaceuticals, LLC: Company and Product Snapshot
Table 139: Sangart, Inc: Company and Product Snapshot
Table 140: Sanguine Biosciences: Company and Product Snapshot
Table 141: Tenax Therapeutics, Inc.: Company and Product Snapshot
Table 142: Therapure Biopharma Inc.: Company and Product Snapshot
Table 143: Abbreviations Used in Artificial Blood Market
Summary Table: Global Potential Artificial Blood Market by case type, Through 2027
Table 1: Historical Events Related to Blood Transfusion
Table 2: Potential Benefits and Application Areas of Artificial Blood
Table 3: The Challenges Associated With the Development of Artificial Blood
Table 4: Average Number of Blood Units Required During Particular Medical Condition
Table 5: Market Penetration Cases Based on Set of Assumptions
Table 6: Global Potential Artificial Blood Market by Case Type, Through 2027
Table 7: Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
Table 8: Pros and Cons of Artificial Blood Developed from Human Blood
Table 9: Pros and Cons of Artificial Blood Developed from Animal Blood
Table 10: Pros & Cons of Artificial Blood Developed from Recombinant Blood
Table 11: Summary of Acellular Hb-Based Oxygen Carriers
Table 12: Hemoglobin Based Oxygen Carrier Products and Approval Status
Table 13: Potential Clinical Applications of Oxygen Carriers
Table 14: Composition of PFC Emulsion Based Artificial Blood Products
Table 15: First-Generation Perfluorocarbon Emulsions Used in Medicine and Biology
Table 16: Comparative Study of Second-Generation PFCs
Table 17: PFC Emulsion Products and Current Status
Table 18: Comparative Study Between RBCs and HBOCs
Table 19: HBOC Solutions Transfusion: Side Effects and Possible Causes
Table 20: HBOC Products Developed by Various Companies
Table 21: Global Potential Artificial Blood Market, by Application, Through 2027
Table 22: United States: Potential Artificial Blood Market, Through 2027
Table 23: Canada: Potential Artificial Blood Market, Through 2027
Table 24: Mexico: Potential Artificial Blood Market, Through 2027
Table 25: Germany: Potential Artificial Blood Market, Through 2027
Table 26: France: Potential Artificial Blood Market, Through 2027
Table 27: U.K.: Potential Artificial Blood Market, Through 2027
Table 28: Italy: Potential Artificial Blood Market, Through 2027
Table 29: Spain: Potential Artificial Blood Market, Through 2027
Table 30: Russia: Potential Artificial Blood Market, Through 2027
Table 31: China: Potential Artificial Blood Market, Through 2027
Table 32: India: Potential Artificial Blood Market, Through 2027
Table 33: Japan: Potential Artificial Blood Market, Through 2027
Table 34: Australia: Potential Artificial Blood Market, Through 2027
Table 35: Brazil: Potential Artificial Blood Market, Through 2027
Table 36: South Africa: Potential Artificial Blood Market, Through 2027
Table 37: Summary of Three Clinical Trial Phases Recognized by FDA
Table 38: Hemolink: Raw Material and Method Overview
Table 39: Hemolink: Advantages and Disadvantages
Table 40: Hemolink Clinical Trials Details
Table 41: Hemolink Clinical Trial: Tracking Information
Table 42: Hemolink Clinical Trial: Descriptive Information
Table 43: Hemolink Clinical Trial: Recruitment Information
Table 44: Hemolink Clinical Trial: Administrative Information
Table 45: HemAssist: Raw Material and Method Overview
Table 46: HemAssist: Product Characteristics
Table 47: HemAssist: Advantages and Disadvantages
Table 48: Hemopure: Raw Material and Method Overview
Table 49: Hemopure: Product Characteristics
Table 50: Hemopure: Advantages and Disadvantages
Table 51: Hemopure: List of Clinical Trials Registered
Table 52: Hemopure Clinical Trial: Patient Information
Table 53: Hemopure Clinical Trial: Details
Table 54: Summary of the Red-Blood-Cell-Controlled Phase 2 and Phase 3 Clinical Trial Performed by Biopure Corp.
Table 55: Red-Blood-Cell-Controlled Clinical Trial Performed on Surgical Patients, by Dosage and Effects
Table 56: Hemopure Clinical Trial: Tracking Information
Table 57: Decriptive Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
Table 58: Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
Table 59: Administrative Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
Table 60: A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects
Table 61: Descriptive Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
Table 62: Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
Table 63: Administrative Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
Table 64: Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia
Table 65: Tracking Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
Table 66: Descriptive Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
Table 67: Recruitment Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
Table 68: Administrative Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia
Table 69: Hemospan: Raw Material and Method Overview
Table 70: Hemospan: Product Characteristics
Table 71: Hemospan: Advantages and Disadvantages
Table 72: Clinical Studies with Hemospan: Completed and Ongoing
Table 73: Hemospan Clinical Trial: Details
Table 74: Hemospan Clinical Trial: Tracking Information
Table 75: Hemospan Clinical Trial: Descriptive Information
Table 76: Hemospan Clinical Trial: Recruitment Information
Table 77: Hemospan Clinical Trial: Administrative Information
Table 78: Hemotech: Raw Material and Method Overview
Table 79: HemoTech: Advantages and Disadvantages
Table 80: HemoTech Clinical Trials: Details
Table 81: HemoTech Clinical Trial: Tracking Information
Table 82: HemoTech Clinical Trial: Descriptive Information
Table 83: HemoTech Clinical Trial: Recruitment Information
Table 84: HemoTech Clinical Trial: Administrative Information
Table 85: DDFPe: Company Product Range and Description
Table 86: DDFPe: Raw Material and Method Overview
Table 87: DDFPe: Advantages and Disadvantages
Table 88: DDFPeClinical Trials: Details
Table 89: DDFPe Clinical Trial: Tracking Information
Table 90: DDFPe Clinical Trial: Descriptive Information
Table 91: DDFPe Clinical Trial: Recruitment Information
Table 92: DDFPe Clinical Trial: Administrative Information
Table 93: Oxycyte: Raw Material and Method Overview
Table 94: Oxycyte: Advantages and Disadvantages
Table 95: Oxycyte Clinical Trials: Details
Table 96: Oxycyte Clinical Trial: Tracking Information
Table 97: Descriptive Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
Table 98: Recruitment Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
Table 99: Administrative Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)
Table 100: Details of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 101: Tracking Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 102: Descriptive Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 103: Recruitment Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 104: Administrative Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury
Table 105: Oxygent: Raw Material and Method Overview
Table 106: Oxygent: Advantages and Disadvantages
Table 107: Oxygent: Clinical Trials
Table 108: Vidaphor: Raw Material and Method Overview
Table 109: Vidaphor: Advantages and Disadvantages
Table 110: Vidaphor: Clinical Trial
Table 111: PHER-O2: Raw Material and Method Overview
Table 112: PHER-O2: Advantages and Disadvantages
Table 113: PHER-O2: Clinical Trials
Table 114: PolyHeme: Raw Material and Method Overview
Table 115: PolyHeme: Product Characteristics
Table 116: PolyHeme: Advantages and Disadvantages
Table 117: Polyheme Clinical Trials: Patient Information
Table 118: PolyHeme Clinical Trial: Details
Table 119: PolyHeme Clinical Trial: Tracking Information
Table 120: PolyHeme Clinical Trial: Descriptive Information
Table 121: PolyHeme Clinical Trial: Recruitment Information
Table 122: PolyHeme Clinical Trial: Administrative Information
Table 123: SANGUINATE: Raw Material and Method Overview
Table 124: SANGUINATE: Advantages and Disadvantages
Table 125: SANGUINATE: Clinical Trials
Table 126: SANGUINATE Clinical Trial: Details
Table 127: SANGUINATE Clinical Trial: Tracking Information
Table 128: SANGUINATE Clinical Trial: Descriptive Information
Table 129: SANGUINATE Clinical Trial: Recruitment Information
Table 130: SANGUINATE Clinical Trial: Administrative Information
Table 131: Alliance Pharmaceutical Corp: Company and Product Snapshot
Table 132: Baxter International Inc.: Company and Product Snapshot
Table 133: Biopure Corp: Company and Product Snapshot
Table 134: FluorO2 Therapeutics Inc.: Company and Product Snapshot
Table 135: HemoBioTech, Inc.: Company and Product Snapshot
Table 136: HemoBioTech, Inc.: Company and Product Snapshot
Table 137: Northfield Laboratories Inc.: Company and Product Snapshot
Table 138: Prolong Pharmaceuticals, LLC: Company and Product Snapshot
Table 139: Sangart, Inc: Company and Product Snapshot
Table 140: Sanguine Biosciences: Company and Product Snapshot
Table 141: Tenax Therapeutics, Inc.: Company and Product Snapshot
Table 142: Therapure Biopharma Inc.: Company and Product Snapshot
Table 143: Abbreviations Used in Artificial Blood Market
LIST OF FIGURES
Summary Figure: Global Potential Artificial Blood Market, 2022–2027
Figure 1: Medical Applications of Human Red Blood Cells
Figure 2: Total Number of Surgeries and Death Cases in the World, 2017–2022
Figure 3: Total Number of Blood Units Transfused in the World, 2017–2027
Figure 4: Global Potential Artificial Blood Market, 2022–2027
Figure 5: Artificial Blood Manufactured from Different Sources
Figure 6: Historical Events of HBOCs Developed Using Recombinant Technology
Figure 7: Classification of Modified Hemoglobin Solution Based on Methods
Figure 8: Classification of Different Types of Oxygen Carriers
Figure 9: Generations of Perfluorocarbon Emulsions
Figure 10: Advantages and Disadvantages of PFC Emulsions
Figure 11: Development of HBOCs
Figure 12: Advantages and Disadvantages of HBOCs
Figure 13: Global Potential Artificial Blood Market, by Application, 2022–2027
Figure 14: United States: Country Snapshot
Figure 15: Heart Disease Trend in the United States
Figure 16: Cancer Disease Trend in the United States
Figure 17: Transport Accident Trend in the United States
Figure 18: Blood Supply in the United States
Figure 19: Blood Demand in the United States
Figure 20: United States: Potential Artificial Blood Market, 2022–2027
Figure 21: Canada: Country Snapshot
Figure 22: Heart Disease Trend in Canada
Figure 23: Cancer Disease Trend in Canada
Figure 24: Transport Accident Trend in Canada
Figure 25: Blood Supply in Canada
Figure 26: Blood Demand in Canada
Figure 27: Canada: Potential Artificial Blood Market, 2022–2027
Figure 28: Mexico: Country Snapshot
Figure 29: Heart Disease Trend in Mexico
Figure 30: Cancer Disease Trend in Mexico
Figure 31: Transport Accident Trend in Mexico
Figure 32: Blood Supply in Mexico
Figure 33: Blood Demand in Mexico
Figure 34: Mexico: Potential Artificial Blood Market, 2022–2027
Figure 35: Germany: Country Snapshot
Figure 36: Heart Disease Trend in Germany
Figure 37: Cancer Disease Trend in Germany
Figure 38: Transport Accident Trend in Germany
Figure 39: Blood Supply in Germany
Figure 40: Blood Demand in Germany
Figure 41: Germany: Potential Artificial Blood Market, 2022–2027
Figure 42: France: Country Snapshot
Figure 43: Heart Disease Trend in France
Figure 44: Cancer Disease Trend in France
Figure 45: Transport Accident Trend in France
Figure 46: Blood Supply in France
Figure 47: Blood Demand (RBCs Transfused) in France
Figure 48: France: Potential Artificial Blood Market, 2022–2027
Figure 49: United Kingdom: Country Snapshot
Figure 50: Heart Disease Trend in the U.K.
Figure 51: Cancer Disease Trend in the U.K.
Figure 52: Transport Accident Trend in the U.K.
Figure 53: Blood Supply in the U.K.
Figure 54: Blood Demand in the U.K.
Figure 55: U.K.: Potential Artificial Blood Market, 2022–2027
Figure 56: Italy: Country Snapshot
Figure 57: Heart Disease Trend in Italy
Figure 58: Cancer Disease Trend in Italy
Figure 59: Transport Accident Trend in Italy
Figure 60: Blood Supply in Italy
Figure 61: Blood Demand in Italy
Figure 62: Italy: Potential Artificial Blood Market, 2022–2027
Figure 63: Spain: Country Snapshot
Figure 64: Heart Disease Trend in Spain
Figure 65: Cancer Disease Trend in Spain
Figure 66: Transport Accident Trend in Spain
Figure 67: Blood Supply in Spain
Figure 68: Blood Demand in Spain
Figure 69: Spain: Potential Artificial Blood Market, 2022–2027
Figure 70: Russia: Country Snapshot
Figure 71: Heart Disease Trend in Russia
Figure 72: Cancer Disease Trend in Russia
Figure 73: Transport Accident Trend in Russia
Figure 74: Blood Supply in Russia
Figure 75: Blood Demand in Russia
Figure 76: Russia: Potential Artificial Blood Market, 2022–2027
Figure 77: China: Country Snapshot
Figure 78: Heart Disease Trend in China
Figure 79: Cancer Disease Trend in China
Figure 80: Transport Accident Trend in China
Figure 81: Blood Supply in China
Figure 82: Blood Demand in China
Figure 83: China: Potential Artificial Blood Market, 2022–2027
Figure 84: India: Country Snapshot
Figure 85: Heart Disease Trend in India
Figure 86: Cancer Disease Trend in India
Figure 87: Transport Accident Trend in India
Figure 88: Blood Supply in India
Figure 89: Blood Demand in India
Figure 90: India: Potential Artificial Blood Market, 2022–2027
Figure 91: Japan: Country Snapshot
Figure 92: Heart Disease Trend in Japan
Figure 93: Cancer Disease Trend in Japan
Figure 94: Transport Accident Trend in Japan
Figure 95: Blood Supply in Japan
Figure 96: Blood Demand in Japan
Figure 97: Japan: Potential Artificial Blood Market, 2022–2027
Figure 98: Australia: Country Snapshot
Figure 99: Heart Disease Trend in Australia
Figure 100: Cancer Disease Trend in Australia
Figure 101: Transport Accident Trend in Australia
Figure 102: Blood Supply in Australia
Figure 103: Blood Demand in Australia
Figure 104: Australia: Potential Artificial Blood Market, 2022–2027
Figure 105: Brazil: Country Snapshot
Figure 106: Heart Disease Trend in Brazil
Figure 107: Cancer Disease Trend in Brazil
Figure 108: Transport Accident Trend in Brazil
Figure 109: Blood Supply in Brazil
Figure 110: Blood Demand in Brazil
Figure 111: Brazil: Potential Artificial Blood Market, 2022–2027
Figure 112: South Africa: Country Snapshot
Figure 113: Heart Disease Trend in South Africa
Figure 114: Cancer Disease Trend in South Africa
Figure 115: Transport Accident Trend in South Africa
Figure 116: Blood Supply in South Africa
Figure 117: Blood Demand in South Africa
Figure 118: South Africa: Potential Artificial Blood Market, 2022–2027
Figure 119: Current Competition in the Global Artificial Blood Market (I), 2020–2022
Figure 120: Current Competition in the Global Artificial Blood Market (II), 2022–2027
Figure 121: Artificial Blood: Parameters for Product Analysis
Figure 122: Hemolink: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 123: HemAssist: Production Flow Chart
Figure 124: HemAssist: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 125: Hemopure: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 126: Hemospan: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 127: HemoTech: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 128: DDFPe: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 129: Oxycyte: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 130: Oxygent: Product Analysis (Based on Safety, Effectiveness, Cost, And Legal Implications)
Figure 131: Vidaphor: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 132: PHER-O2: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 133: PolyHeme: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 134: SANGUINATE: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Summary Figure: Global Potential Artificial Blood Market, 2022–2027
Figure 1: Medical Applications of Human Red Blood Cells
Figure 2: Total Number of Surgeries and Death Cases in the World, 2017–2022
Figure 3: Total Number of Blood Units Transfused in the World, 2017–2027
Figure 4: Global Potential Artificial Blood Market, 2022–2027
Figure 5: Artificial Blood Manufactured from Different Sources
Figure 6: Historical Events of HBOCs Developed Using Recombinant Technology
Figure 7: Classification of Modified Hemoglobin Solution Based on Methods
Figure 8: Classification of Different Types of Oxygen Carriers
Figure 9: Generations of Perfluorocarbon Emulsions
Figure 10: Advantages and Disadvantages of PFC Emulsions
Figure 11: Development of HBOCs
Figure 12: Advantages and Disadvantages of HBOCs
Figure 13: Global Potential Artificial Blood Market, by Application, 2022–2027
Figure 14: United States: Country Snapshot
Figure 15: Heart Disease Trend in the United States
Figure 16: Cancer Disease Trend in the United States
Figure 17: Transport Accident Trend in the United States
Figure 18: Blood Supply in the United States
Figure 19: Blood Demand in the United States
Figure 20: United States: Potential Artificial Blood Market, 2022–2027
Figure 21: Canada: Country Snapshot
Figure 22: Heart Disease Trend in Canada
Figure 23: Cancer Disease Trend in Canada
Figure 24: Transport Accident Trend in Canada
Figure 25: Blood Supply in Canada
Figure 26: Blood Demand in Canada
Figure 27: Canada: Potential Artificial Blood Market, 2022–2027
Figure 28: Mexico: Country Snapshot
Figure 29: Heart Disease Trend in Mexico
Figure 30: Cancer Disease Trend in Mexico
Figure 31: Transport Accident Trend in Mexico
Figure 32: Blood Supply in Mexico
Figure 33: Blood Demand in Mexico
Figure 34: Mexico: Potential Artificial Blood Market, 2022–2027
Figure 35: Germany: Country Snapshot
Figure 36: Heart Disease Trend in Germany
Figure 37: Cancer Disease Trend in Germany
Figure 38: Transport Accident Trend in Germany
Figure 39: Blood Supply in Germany
Figure 40: Blood Demand in Germany
Figure 41: Germany: Potential Artificial Blood Market, 2022–2027
Figure 42: France: Country Snapshot
Figure 43: Heart Disease Trend in France
Figure 44: Cancer Disease Trend in France
Figure 45: Transport Accident Trend in France
Figure 46: Blood Supply in France
Figure 47: Blood Demand (RBCs Transfused) in France
Figure 48: France: Potential Artificial Blood Market, 2022–2027
Figure 49: United Kingdom: Country Snapshot
Figure 50: Heart Disease Trend in the U.K.
Figure 51: Cancer Disease Trend in the U.K.
Figure 52: Transport Accident Trend in the U.K.
Figure 53: Blood Supply in the U.K.
Figure 54: Blood Demand in the U.K.
Figure 55: U.K.: Potential Artificial Blood Market, 2022–2027
Figure 56: Italy: Country Snapshot
Figure 57: Heart Disease Trend in Italy
Figure 58: Cancer Disease Trend in Italy
Figure 59: Transport Accident Trend in Italy
Figure 60: Blood Supply in Italy
Figure 61: Blood Demand in Italy
Figure 62: Italy: Potential Artificial Blood Market, 2022–2027
Figure 63: Spain: Country Snapshot
Figure 64: Heart Disease Trend in Spain
Figure 65: Cancer Disease Trend in Spain
Figure 66: Transport Accident Trend in Spain
Figure 67: Blood Supply in Spain
Figure 68: Blood Demand in Spain
Figure 69: Spain: Potential Artificial Blood Market, 2022–2027
Figure 70: Russia: Country Snapshot
Figure 71: Heart Disease Trend in Russia
Figure 72: Cancer Disease Trend in Russia
Figure 73: Transport Accident Trend in Russia
Figure 74: Blood Supply in Russia
Figure 75: Blood Demand in Russia
Figure 76: Russia: Potential Artificial Blood Market, 2022–2027
Figure 77: China: Country Snapshot
Figure 78: Heart Disease Trend in China
Figure 79: Cancer Disease Trend in China
Figure 80: Transport Accident Trend in China
Figure 81: Blood Supply in China
Figure 82: Blood Demand in China
Figure 83: China: Potential Artificial Blood Market, 2022–2027
Figure 84: India: Country Snapshot
Figure 85: Heart Disease Trend in India
Figure 86: Cancer Disease Trend in India
Figure 87: Transport Accident Trend in India
Figure 88: Blood Supply in India
Figure 89: Blood Demand in India
Figure 90: India: Potential Artificial Blood Market, 2022–2027
Figure 91: Japan: Country Snapshot
Figure 92: Heart Disease Trend in Japan
Figure 93: Cancer Disease Trend in Japan
Figure 94: Transport Accident Trend in Japan
Figure 95: Blood Supply in Japan
Figure 96: Blood Demand in Japan
Figure 97: Japan: Potential Artificial Blood Market, 2022–2027
Figure 98: Australia: Country Snapshot
Figure 99: Heart Disease Trend in Australia
Figure 100: Cancer Disease Trend in Australia
Figure 101: Transport Accident Trend in Australia
Figure 102: Blood Supply in Australia
Figure 103: Blood Demand in Australia
Figure 104: Australia: Potential Artificial Blood Market, 2022–2027
Figure 105: Brazil: Country Snapshot
Figure 106: Heart Disease Trend in Brazil
Figure 107: Cancer Disease Trend in Brazil
Figure 108: Transport Accident Trend in Brazil
Figure 109: Blood Supply in Brazil
Figure 110: Blood Demand in Brazil
Figure 111: Brazil: Potential Artificial Blood Market, 2022–2027
Figure 112: South Africa: Country Snapshot
Figure 113: Heart Disease Trend in South Africa
Figure 114: Cancer Disease Trend in South Africa
Figure 115: Transport Accident Trend in South Africa
Figure 116: Blood Supply in South Africa
Figure 117: Blood Demand in South Africa
Figure 118: South Africa: Potential Artificial Blood Market, 2022–2027
Figure 119: Current Competition in the Global Artificial Blood Market (I), 2020–2022
Figure 120: Current Competition in the Global Artificial Blood Market (II), 2022–2027
Figure 121: Artificial Blood: Parameters for Product Analysis
Figure 122: Hemolink: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 123: HemAssist: Production Flow Chart
Figure 124: HemAssist: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 125: Hemopure: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 126: Hemospan: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 127: HemoTech: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 128: DDFPe: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)
Figure 129: Oxycyte: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 130: Oxygent: Product Analysis (Based on Safety, Effectiveness, Cost, And Legal Implications)
Figure 131: Vidaphor: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 132: PHER-O2: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 133: PolyHeme: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
Figure 134: SANGUINATE: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)
